Interleukin-6 Could Be a Potential Prognostic Factor in Ambulatory Elderly Patients with Stable Heart Failure: Results from a Pilot Study

Introduction: Inflammation is a fundamental phenomenon in heart failure, but the prognostic or therapeutic role of markers such as interleukin-6 (IL-6) has not yet been clarified. The objective of this study is to describe the clinical profile of patients with elevated IL-6 and determine if they hav...

Full description

Bibliographic Details
Main Authors: Marina Povar-Echeverría, Pablo Esteban Auquilla-Clavijo, Emmanuel Andrès, Francisco Javier Martin-Sánchez, María Victoria Laguna-Calle, Alberto Elpidio Calvo-Elías, Noel Lorenzo-Villalba, Manuel Méndez-Bailón
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/10/3/504
id doaj-cdaaa3e14d2e463c8d740d99ec3face2
record_format Article
spelling doaj-cdaaa3e14d2e463c8d740d99ec3face22021-02-02T00:01:05ZengMDPI AGJournal of Clinical Medicine2077-03832021-02-011050450410.3390/jcm10030504Interleukin-6 Could Be a Potential Prognostic Factor in Ambulatory Elderly Patients with Stable Heart Failure: Results from a Pilot StudyMarina Povar-Echeverría0Pablo Esteban Auquilla-Clavijo1Emmanuel Andrès2Francisco Javier Martin-Sánchez3María Victoria Laguna-Calle4Alberto Elpidio Calvo-Elías5Noel Lorenzo-Villalba6Manuel Méndez-Bailón7Servicio de Medicina Interna, Hospital Universitario Miguel Servet, 50009 Zaragoza, SpainServicio de Cardiología, Hospital Royo Villanova, 50015 Zaragoza, SpainService de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, FranceServicio de Medicina Interna, Facultad de Medicina, Instituto de Investigación Sanitaria del Hospital San Carlos, Hospital Clínico San Carlos, Universidad Complutense de Madrid, 28040 Madrid, SpainServicio de Medicina Interna, Facultad de Medicina, Instituto de Investigación Sanitaria del Hospital San Carlos, Hospital Clínico San Carlos, Universidad Complutense de Madrid, 28040 Madrid, SpainServicio de Medicina Interna, Facultad de Medicina, Instituto de Investigación Sanitaria del Hospital San Carlos, Hospital Clínico San Carlos, Universidad Complutense de Madrid, 28040 Madrid, SpainService de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, FranceServicio de Medicina Interna, Facultad de Medicina, Instituto de Investigación Sanitaria del Hospital San Carlos, Hospital Clínico San Carlos, Universidad Complutense de Madrid, 28040 Madrid, SpainIntroduction: Inflammation is a fundamental phenomenon in heart failure, but the prognostic or therapeutic role of markers such as interleukin-6 (IL-6) has not yet been clarified. The objective of this study is to describe the clinical profile of patients with elevated IL-6 and determine if they have worse clinical outcomes. Methods: A retrospective c.ohort observational study including 78 patients with heart failure followed up at the Heart Failure Outpatient Clinic of the Internal Medicine Department. IL-6 was determined in all patients, who were then assigned into two groups according to IL-6 level (normal or high). Clinical and prognostic data were collected to determine the differences in both groups. Results: The average age was 79 years, 60% female. A total of 53.8% of the patients had elevated IL-6 (group 2). Patients with elevated IL-6 presented more frequently with anemia mellitus (64.3% vs. 41.7%; <i>p</i> = 0.046), atrial fibrillation (83.3% vs. 61.9% <i>p</i> = 0.036), dyslipidemia (76.2% vs. 58.2%; <i>p</i> = 0.03), higher creatinine levels (1.35 mg/dL vs. 1.08 mg/dL; <i>p</i> = 0.024), lower glomerular filtration rate (43.6 mL/min/m<sup>2</sup> vs. 59.9 mL/min/m<sup>2</sup>; <i>p</i> = 0.007), and anemia 25% vs. 52.4% <i>p</i> = 0.014. The factors independently associated with the increase in IL-6 were anemia 3.513 (1.163–10.607) and renal failure 0.963 (0.936–0.991), <i>p</i> < 0.05. Mortality was higher in the group with elevated IL-6 levels (16% vs. 2%; <i>p</i> = 0.044) with a log-rank <i>p</i> = 0.027 in the Kaplan–Meier curve. Conclusion: Patients with heart failure and elevated IL-6 most often have atrial fibrillation, diabetes mellitus, dyslipidemia, anemia, and renal failure. In addition, mortality was higher and a tendency of higher hospital admission was observed in stable HF patients with elevated IL-6.https://www.mdpi.com/2077-0383/10/3/504heart failurebiomarkersinflammationsinterleukin-6
collection DOAJ
language English
format Article
sources DOAJ
author Marina Povar-Echeverría
Pablo Esteban Auquilla-Clavijo
Emmanuel Andrès
Francisco Javier Martin-Sánchez
María Victoria Laguna-Calle
Alberto Elpidio Calvo-Elías
Noel Lorenzo-Villalba
Manuel Méndez-Bailón
spellingShingle Marina Povar-Echeverría
Pablo Esteban Auquilla-Clavijo
Emmanuel Andrès
Francisco Javier Martin-Sánchez
María Victoria Laguna-Calle
Alberto Elpidio Calvo-Elías
Noel Lorenzo-Villalba
Manuel Méndez-Bailón
Interleukin-6 Could Be a Potential Prognostic Factor in Ambulatory Elderly Patients with Stable Heart Failure: Results from a Pilot Study
Journal of Clinical Medicine
heart failure
biomarkers
inflammations
interleukin-6
author_facet Marina Povar-Echeverría
Pablo Esteban Auquilla-Clavijo
Emmanuel Andrès
Francisco Javier Martin-Sánchez
María Victoria Laguna-Calle
Alberto Elpidio Calvo-Elías
Noel Lorenzo-Villalba
Manuel Méndez-Bailón
author_sort Marina Povar-Echeverría
title Interleukin-6 Could Be a Potential Prognostic Factor in Ambulatory Elderly Patients with Stable Heart Failure: Results from a Pilot Study
title_short Interleukin-6 Could Be a Potential Prognostic Factor in Ambulatory Elderly Patients with Stable Heart Failure: Results from a Pilot Study
title_full Interleukin-6 Could Be a Potential Prognostic Factor in Ambulatory Elderly Patients with Stable Heart Failure: Results from a Pilot Study
title_fullStr Interleukin-6 Could Be a Potential Prognostic Factor in Ambulatory Elderly Patients with Stable Heart Failure: Results from a Pilot Study
title_full_unstemmed Interleukin-6 Could Be a Potential Prognostic Factor in Ambulatory Elderly Patients with Stable Heart Failure: Results from a Pilot Study
title_sort interleukin-6 could be a potential prognostic factor in ambulatory elderly patients with stable heart failure: results from a pilot study
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2021-02-01
description Introduction: Inflammation is a fundamental phenomenon in heart failure, but the prognostic or therapeutic role of markers such as interleukin-6 (IL-6) has not yet been clarified. The objective of this study is to describe the clinical profile of patients with elevated IL-6 and determine if they have worse clinical outcomes. Methods: A retrospective c.ohort observational study including 78 patients with heart failure followed up at the Heart Failure Outpatient Clinic of the Internal Medicine Department. IL-6 was determined in all patients, who were then assigned into two groups according to IL-6 level (normal or high). Clinical and prognostic data were collected to determine the differences in both groups. Results: The average age was 79 years, 60% female. A total of 53.8% of the patients had elevated IL-6 (group 2). Patients with elevated IL-6 presented more frequently with anemia mellitus (64.3% vs. 41.7%; <i>p</i> = 0.046), atrial fibrillation (83.3% vs. 61.9% <i>p</i> = 0.036), dyslipidemia (76.2% vs. 58.2%; <i>p</i> = 0.03), higher creatinine levels (1.35 mg/dL vs. 1.08 mg/dL; <i>p</i> = 0.024), lower glomerular filtration rate (43.6 mL/min/m<sup>2</sup> vs. 59.9 mL/min/m<sup>2</sup>; <i>p</i> = 0.007), and anemia 25% vs. 52.4% <i>p</i> = 0.014. The factors independently associated with the increase in IL-6 were anemia 3.513 (1.163–10.607) and renal failure 0.963 (0.936–0.991), <i>p</i> < 0.05. Mortality was higher in the group with elevated IL-6 levels (16% vs. 2%; <i>p</i> = 0.044) with a log-rank <i>p</i> = 0.027 in the Kaplan–Meier curve. Conclusion: Patients with heart failure and elevated IL-6 most often have atrial fibrillation, diabetes mellitus, dyslipidemia, anemia, and renal failure. In addition, mortality was higher and a tendency of higher hospital admission was observed in stable HF patients with elevated IL-6.
topic heart failure
biomarkers
inflammations
interleukin-6
url https://www.mdpi.com/2077-0383/10/3/504
work_keys_str_mv AT marinapovarecheverria interleukin6couldbeapotentialprognosticfactorinambulatoryelderlypatientswithstableheartfailureresultsfromapilotstudy
AT pabloestebanauquillaclavijo interleukin6couldbeapotentialprognosticfactorinambulatoryelderlypatientswithstableheartfailureresultsfromapilotstudy
AT emmanuelandres interleukin6couldbeapotentialprognosticfactorinambulatoryelderlypatientswithstableheartfailureresultsfromapilotstudy
AT franciscojaviermartinsanchez interleukin6couldbeapotentialprognosticfactorinambulatoryelderlypatientswithstableheartfailureresultsfromapilotstudy
AT mariavictorialagunacalle interleukin6couldbeapotentialprognosticfactorinambulatoryelderlypatientswithstableheartfailureresultsfromapilotstudy
AT albertoelpidiocalvoelias interleukin6couldbeapotentialprognosticfactorinambulatoryelderlypatientswithstableheartfailureresultsfromapilotstudy
AT noellorenzovillalba interleukin6couldbeapotentialprognosticfactorinambulatoryelderlypatientswithstableheartfailureresultsfromapilotstudy
AT manuelmendezbailon interleukin6couldbeapotentialprognosticfactorinambulatoryelderlypatientswithstableheartfailureresultsfromapilotstudy
_version_ 1724314858559635456